Drug intelligence / Profile preview

Slimwell

Development stage: Preclinical
Lead developer: Benswell
Administration: Oral

Overview

Slimwell is a high-protein meal replacement product manufactured by Benswell Corporation in Bangkok, Thailand. It is designed to be consumed as a partial meal replacement, with each sachet containing 912.5 kJ (218 kcal), 46% carbohydrate, 29% protein, and 25% fat. It is intended to assist in weight loss and improve metabolic syndrome components, particularly glycemic control, by reducing overall energy and carbohydrate intake and enhancing satiety through its high protein content.

Brand names: Slimwell

Beyond the preview

Go deeper on Slimwell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Slimwell.

Explore the full profile